Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE CONCENTRATE W DEXTROSE 50 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE CONCENTRATE W DEXTROSE 50 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides dextrose as a caloric source and electrolyte replacement in peritoneal dialysis. Dextrose is metabolized to carbon dioxide and water, generating ATP. The high osmolality of the solution promotes ultrafiltration of fluid across the peritoneal membrane, facilitating removal of uremic toxins and excess fluid.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
Not applicable; dialysate concentrate is used in hemodialysis machines, not administered directly to patients. Dextrose concentration in final dialysate is typically 1.5-2.5 g/dL depending on prescription.
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
None Documented
None Documented
Not applicable as a fixed half-life; glucose has a plasma elimination half-life of approximately 15-20 minutes, but this is concentration-dependent. Dialysis solutions are not administered as a single intravenous dose; the components are continuously infused.
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Renal excretion of glucose and electrolytes; glucose is completely reabsorbed or metabolized, while electrolytes are excreted proportionally to serum levels and renal function. 100% renal elimination of administered electrolytes.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution